Abstract
Twenty three dual PPAR alpha and gamma molecules of natural product origin, previously reported by our group, were further investigated for pan PPAR transactivation against PPAR delta. The in vitro cell toxicity profile, as well as, in silico study of the most active molecules within this new class of pan PPAR agonists are also described. 3',5' Dimethoxy-7 hydroxyisoflavone 6, Psi-baptigenin 7, 4' fluoro-7 hydroxyisoflavone 8, and 3' methoxy-7 hydroxyisoflavone 9 were identified as the most potent molecules studied within the set compared to the commercially available pan PPAR agonist, bezafibrate 1. These novel active molecules may thus be useful as future leads in PPAR-related disorders, including type II diabetes mellitus and metabolic syndrome.
| Original language | English |
|---|---|
| Pages (from-to) | 766-778 |
| Number of pages | 13 |
| Journal | Bioorganic & Medicinal Chemistry |
| Volume | 21 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- cells
- ligand
- metabolism
- non-insulin-dependent diabetes
Fingerprint
Dive into the research topics of 'The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver